World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
33812
World Ranking
15409
National Ranking
7772

Overview

Paul J. Catalano is affiliated with Harvard University in the United States and has contributed extensively to the field of medicine, with a strong emphasis on oncology and related subfields. Their publication record includes a significant number of works focused on pulmonary and respiratory medicine, oncology, genetics, cancer research, and radiology, nuclear medicine, and imaging.

The subfields covered by their research include:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Genetics
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging

The research topics Paul J. Catalano has worked on cover various critical areas in medical oncology:

  • Brain Metastases and Treatment
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Renal Cell Carcinoma Treatment
  • Cancer Immunotherapy and Biomarkers
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics

Among recent papers authored or coauthored by Catalano are:

  • Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (2022, Journal of Clinical Oncology)
  • Large language models to identify social determinants of health in electronic health records (2024, npj Digital Medicine)
  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 (2023, Journal of Clinical Oncology)
  • KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1 (2020, Cancer Immunology Research)
  • Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma (2020, Clinical Cancer Research)

Frequent coauthors include:

  • Daphne A. Haas-Kogan (35 collaborative papers)
  • Ayal A. Aizer (32 collaborative papers)
  • Daniel Cagney (23 collaborative papers)
  • Nayan Lamba (22 collaborative papers)
  • Patrick Y. Wen (20 collaborative papers)

The primary publication venues where Catalano's research appears most often encompass:

  • Journal of Clinical Oncology (29 publications)
  • International Journal of Radiation Oncology*Biology*Physics (15 publications)
  • Neuro-Oncology (11 publications)
  • Journal for ImmunoTherapy of Cancer (4 publications)
  • JNCI Journal of the National Cancer Institute (4 publications)

Paul J. Catalano's research contributions predominantly focus on clinical and translational aspects of cancer treatment, diagnosis, and biomarker identification, drawing upon interdisciplinary approaches across multiple oncology subfields. Their collaboration network and publication venues reflect sustained involvement in high-impact clinical oncology research.

Best Publications

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089

    T.E. Le Voyer;E.R. Sigurdson;A.L. Hanlon;R.J. Mayer

  • Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer

    Jane C. Weeks;Paul J. Catalano;Angel Cronin;Matthew D. Finkelman

  • Molecular predictors of survival after adjuvant chemotherapy for colon cancer.

    Toshiaki Watanabe;Tsung Teh Wu;Paul J. Catalano;Paul J. Catalano;Takashi Ueki

  • Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

    Jordan D. Berlin;Paul Catalano;James P. Thomas;John W. Kugler

  • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

    David A. Braun;David A. Braun;Yue Hou;Ziad Bakouny;Miriam Ficial;Miriam Ficial

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

  • Under-reporting of alcohol consumption in household surveys: a comparison of quantity-frequency, graduated-frequency and recent recall.

    Tim Stockwell;Susan Donath;Mark Cooper-Stanbury;Tanya Chikritzhs

  • Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

    Daniel N Cagney;Allison M Martin;Paul J Catalano;Amanda J Redig

  • Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes

    Adam C. Berger;Elin R. Sigurdson;Thomas LeVoyer;Alexandra Hanlon

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer.

    Daniel N. Cagney;Allison M. Martin;Paul J. Catalano;Paul D. Brown

  • Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089

    Daniel G. Haller;Paul J. Catalano;John S. Macdonald;Mark A. O'Rourke

  • Impact of diabetes mellitus on outcomes in patients with colon cancer.

    Jeffrey A. Meyerhardt;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

  • Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281

    Weijing Sun;Stuart Lipsitz;Paul Catalano;James A. Mailliard

  • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200

    B. J. Giantonio;P. J. Catalano;N. J. Meropol;P. J. O'Dwyer

  • Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

    C R Nichols;P J Catalano;E D Crawford;N J Vogelzang

  • Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

    Jeffrey A. Meyerhardt;Paul J. Catalano;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

  • Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

    Malcolm A. Smith;Lawrence Rubinstein;James R. Anderson;Diane Arthur

  • Impact o f D iabetes M ellitus o n O utcomes i n P atients W ith Colon C ancer

    Jeffrey A. Meyerhardt;Paul J. Catalano;Daniel G. Haller;Robert J. Mayer

Frequent Co-Authors

Al B. Benson
Al B. Benson Northwestern University
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Brian M. Alexander
Brian M. Alexander Foundation Medicine
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
Peter J. O'Dwyer
Peter J. O'Dwyer University of Pennsylvania
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Robert I. Haddad
Robert I. Haddad Harvard University
Petros Koutrakis
Petros Koutrakis Harvard University
Tanya Chikritzhs
Tanya Chikritzhs Curtin University
Robert J. Mayer
Robert J. Mayer Dana-Farber Cancer Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t have to follow a traditional route. There are many flexible online degree options that allow students to enter or advance within the healthcare field. For instance, bsn to np programs online offer registered nurses the opportunity to become nurse practitioners with a psychiatric mental health focus, entirely from home. This flexibility is ideal for working professionals.

Want to focus on healthcare management? Choosing an affordable healthcare administration degree online or exploring affordable mha online programs can open doors to leadership roles in hospitals, clinics, and organizations, without the high cost of traditional education.

Those looking for the highest clinical expertise may consider cheap online dnp programs, which prepare nurses for advanced practice and leadership roles. These alternative pathways allow students to balance education and life while moving toward impactful roles in healthcare—proving you can achieve your career goals without being limited by geography or high tuition.

Best Scientists Citing Paul J. Catalano

Trending Scientists